1 / 6

RMM Update 020309

RMM Update 020309. PMX 290/2058 – JNK/p38 activation. ← phospho p38. ← total p38. ← phospho JNK ←. ← total JNK ←. 0 1 2 3 4 5 6 7 24h 0.5 uM PMX 290. PMX 290/2058 – Caspase 3 Activation. Caspase 3 is effector of apoptosis Pro caspase is 35 kDa

jermaine-alford
Download Presentation

RMM Update 020309

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RMM Update 020309

  2. PMX 290/2058 – JNK/p38 activation ← phospho p38 ← total p38 ← phosphoJNK ← ← total JNK ← 0 1 2 3 4 5 6 7 24h 0.5 uM PMX 290

  3. PMX 290/2058 – Caspase 3 Activation • Caspase 3 is effector of apoptosis • Pro caspase is 35 kDa • Antibody that recognises only the large cleavage product (19/17 kDa) • HCT116 cells treated with PMX 290 or PMX2058 • Camptothecin 0.5 uM as +ve control 33 25 17 ? ← 17/19 kDa ← D 0.1 0.5 1 5 0.1 0.5 1 5 0.5 PMX 290 PMX 2058 CPT

  4. PMX 290/2058 – PARP Cleavage • PARP 113 kDa • Cleaved to 89 kDa and 24kDa by caspases (e.g. caspase 3) • Prevents DNA repair during apoptosis • HCT116 cells treated with PMX 290 or PMX2058 • Camptothecin (0.5 uM as +ve control 175 83 62 48 33 25 ← 113 kDa ← 89 kDa NS? ← 24 kDa D 0.1 0.5 1 5 0.1 0.5 1 5 0.5 PMX 290 PMX 2058 CPT

  5. PMX 290/2058 – ROS Induction A549 PMX 290 PMX 2058

  6. PMX 290 - Clonogenic growth following 2h treatment

More Related